Biomedcode has developed a new humanized mouse line overexpressing human IL23p19. These mice develop spontaneous phenotypes including dermatitis lesions in jaw-neck area, ear thickening, enlarged draining lymph nodes, spleenomegaly and more. The skin pathology, that has features of atopic dermatitis, gets significantly ameliorated upon treatment with  anti-hIL23p19, rendering this mouse model a nice tool for the efficacy evaluation of therapeutics targeting this key molecule.

While the phenotypes are  further analyzed the dermatitis model  is available for preclinical evaluation.

 

 

 

With a new publication in Arthritis Research and Therapy, entitled “Ectopic bone formation and systemic bone loss in a transmembrane TNF-driven model of human spondyloarthritis”, Biomedcode in collaboration with George Kollias Lab at BSRC Al. Fleming, introduce the TgA86 transmembrane TNF transgenic mouse as a novel model of human spondyloarthritis (SpA).

The authors show that the TgA86 mouse model develops spontaneously peripheral arthritis and axial pathologies that closely reproduce key pathogenic features of human SpA, including distinct stages of inflammation and ectopic new bone formation. This is a chronic and complex disease model that similar to human patients also develops extraarticular comorbidities such as heart valve pathology and systemic bone loss. As with human patients in the clinic, all the pathologies of the TgA86 mouse model are reversed following early treatment with anti-hTNF therapeutics.

This novel model of SpA that captures not only specific features, but also the complexity of human disease, can prove to be an invaluable translational tool in the study of SpA pathogenesis as well as in the evaluation of human therapeutics. Read More

Biomedcode is excited to participate as one of the 63 European companies that have been selected to join the EUGATEWAY Healthcare and Medical Technologies Business Mission to Singapore on 8-11 December 2020. Due to the COVID-19 pandemic this will be a virtual event and we look forward to discussing with potential new partners and clients about future collaborations!

 

 

During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy. Here, we used an immunoglobulin
G1 (IgG1) hinge as an Ab lock to cover the TNFα-binding site of Infliximab by linking it with matrix metalloproteinase (MMP) -2/9 substrate to generate pro-Infliximab that can be specif- ically activated in the RA region to enhance the selectivity and safety of treatment. The Ab lock significantly inhibits the TNFα binding and reduces the anti-idiotypic (anti-Id) Ab binding to pro-Infliximab by 395-fold, 108-fold compared with Infliximab, respectively, and MMP-2/9 can completely restore the TNFα neutralizing ability of pro-Infliximab to block TNFα down- stream signaling. Pro-Infliximab was only selectively activated in the disease site (mouse paws) and presented similar pharmacokinetics (PKs) and bio-distribution to Infliximab. Fur- thermore, pro-Infliximab not only provided equivalent therapeutic efficacy to Infliximab but also maintained mouse immunity against Listeria infection in the RA mouse model, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%). The high-selectivity pro-Infliximab maintains host immunity and keeps the original therapeu- tic efficiency, providing a novel strategy for RA therapy.

Read More

In response to the current outbreak of coronavirus disease (COVID-19), Biomedcode has implemented measures to help ensure the health and safety of our employees as well as their families but to also ensure the welfare of the mice under our care as well as the uninterrupted provision of services under the same high standards of quality.

Greece is currently implementing a “Stay At Home” order, intended to minimize the spread of the disease. In this context Biomedcode has adjusted its operation so that personnel that can work from home are doing so, while personnel essential for the proper operation of our animal facilities as well as the execution of contracted research activities, are provided with the necessary documentation to ensure their on-site presence. 

With a long-standing mission to support biomedical research and drug development, Biomedcode is closely monitoring the scientific findings of this pandemic and is open to contributing with its  preclinical mouse models in the global effort to fight this pandemic.

We will continue to take all necessary precautions and we will be happy to address any questions or concerns you may at info@biomedcode.com.

 

 

Targeting TNF-α as a treatment modality has shown tremendous success, however there are several limitations associated with the current anti-TNF-α biologic drugs including: immunogenicity, life-threatening infections, resistance to treatment, complexity of manufacture and cost of treatment. Ubah et al.  report the in vivo efficacy of novel anti-TNF-α formats generated from molecular engineering of variable new antigen receptors (VNARs), originally derived from the immune system of an immunized nurse shark.

Read More